The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
Open Access
- 1 September 2009
- journal article
- Published by Taylor & Francis Ltd in Clinical and Experimental Gastroenterology
- Vol. 2, 101-109
- https://doi.org/10.2147/ceg.s4512
Abstract
Peer reviewed article authored by (Lauran Vogelaar, Adriaan van’t Spijker, C Janneke van der Woude). Read article or submit your manuscript for publishing.Keywords
This publication has 65 references indexed in Scilit:
- Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s diseaseInternational Journal of Colorectal Disease, 2007
- Mesalamine capsules enhance the quality of life for patients with ulcerative colitisAlimentary Pharmacology & Therapeutics, 2007
- Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosisEuropean Journal of Gastroenterology & Hepatology, 2005
- Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 2004
- Cost of Illness of Crohn??s DiseasePharmacoEconomics, 2002
- Impact of Inflammatory Bowel Disease on Health-Related Quality of LifeDigestive Diseases, 1999
- Determining Clinically Important Differences in Health Status MeasuresPharmacoEconomics, 1999
- A 12-Item Short-Form Health SurveyMedical Care, 1996
- Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's diseaseDigestive Diseases and Sciences, 1995
- THE RELATIONSHIP OF PSYCHIATRIC ILLNESS WITH GASTROINTESTINAL DISEASEAnnual Review of Medicine, 1995